Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368

EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types

Baselga, J., Rischin, D., Ranson, M., Calvert, H., Raymond, E., Kieback, D. G., Kaye, S. B., Gianni, L., Harris, A., Bjork, T., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.03.100 · Cited by 829

Differential Effects of Gefitinib and Cetuximab on Non–small-cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations

Mukohara, T., Engelman, J. A., Hanna, N. H., Yeap, B. Y., Kobayashi, S. S., Lindeman, N. I., Halmos, B., Pearlberg, J., Tsuchihashi, Z., Cantley, L. C., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji238 · Cited by 314

Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Japanese patients with solid malignant tumors

Nakagawa, K., Tamura, T., Negoro, S., Kudoh, S., Yamamoto, N., Yamamoto, N., Takeda, K., Swaisland, H., Nakatani, I., Hirose, M., et al. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg250 · Cited by 277

High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib

Omuro, A. M. P., Kris, M. G., Miller, V. A., Franceschi, E., Shah, N. T., Milton, D. T., & Abrey, L. E. (2005) · Cancer · doi:10.1002/cncr.21033 · Cited by 227

A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening

Jänne, P. A., Borras, A. M., Kuang, Y., Rogers, A. M., Joshi, V. A., Liyanage, H., Lindeman, N., Lee, J. C., Halmos, B., Maher, E. A., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2047 · Cited by 214

A sensitive assay for ZD1839 (Iressa) in human plasma by liquid–liquid extraction and high performance liquid chromatography with mass spectrometric detection: validation and use in Phase I clinical trials

Jones, H., Stafford, L. E., Swaisland, H., & Payne, R. K. (2002) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/s0731-7085(02)00014-6 · Cited by 63

International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

Travis, W. D., Brambilla, E. M., Noguchi, M., Nicholson, A. G., Geisinger, K. R., Yatabe, Y., Beer, D. G., Powell, C. A., Riely, G. J., Schil, P. E. V., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318206a221 · Cited by 4,834

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

Pao, W., & Chmielecki, J. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2947 · Cited by 1,083

Acquired resistance to TKIs in solid tumours: learning from lung cancer

Camidge, D. R., Pao, W., & Sequist, L. V. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.104 · Cited by 862

Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.

Jackman, D., Pao, W., Riely, G. J., Engelman, J. A., Kris, M. G., Jänne, P. A., Lynch, T., Johnson, B. E., & Miller, V. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.7049 · Cited by 793

Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors

Westover, D., Zugazagoitia, J., Cho, B. C., Lovly, C. M., & Paz-Ares, L. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx703 · Cited by 766

Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer

Weickhardt, A. J., Scheier, B., Burke, J. M., Gan, G., Lu, X., Bunn, P. A., Aisner, D. L., Gaspar, L. E., Kavanagh, B. D., Doebele, R. C., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182745948 · Cited by 684

Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation

Oxnard, G. R., Arcila, M. E., Sima, C. S., Riely, G. J., Chmielecki, J., Kris, M. G., Pao, W., Ladanyi, M., & Miller, V. A. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2692 · Cited by 627

Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastases

Costa, D. B., Shaw, A. T., Ou, S. I., Solomon, B., Riely, G. J., Ahn, M., Zhou, C., Shreeve, S. M., Selaru, P., Polli, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.0539 · Cited by 608

CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib

Costa, D. B., Kobayashi, S. S., Pandya, S. S., Yeo, W.-L., Shen, Z., Tan, W., & Wilner, K. D. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.1313 · Cited by 603

Clinical pharmacokinetics of tyrosine kinase inhibitors

van Erp, N. P., Gelderblom, H., & Guchelaar, H.-J. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.08.004 · Cited by 503

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant Disease

Ohashi, K., Maruvka, Y. E., Michor, F., & Pao, W. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.3912 · Cited by 467

Phase II Trial of Lapatinib for Brain Metastases in Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Lin, N., Carey, L., Liu, M., Younger, J., Come, S. E., Ewend, M. G., Harris, G. J., Bullitt, E., den Abbeele, A. D. V., Henson, J. W., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.3588 · Cited by 456

Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid

Pentsova, E. I., Shah, R. H., Tang, J., Boire, A. A., You, D., Briggs, S. R., Omuro, A. M. P., Lin, X., Fleisher, M., Grommes, C., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.6487 · Cited by 421

First-Line Afatinib versus Chemotherapy in Patients with Non–Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases

Schuler, M., Wu, Y.-L., Hirsh, V., O’Byrne, K., Yamamoto, N., Mok, T., Popat, S., Sequist, L. V., Massey, D., Zazulina, V., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.11.014 · Cited by 361

Update on Epidermal Growth Factor Receptor Mutations in Non–Small Cell Lung Cancer

Riely, G. J., Politi, K. A., Miller, V. A., & Pao, W. J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0658 · Cited by 363

New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer

Oxnard, G. R., Arcila, M. E., Chmielecki, J., Ladanyi, M., Miller, V. A., & Pao, W. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2571 · Cited by 359

“Pulsatile” high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer

Grommes, C., Oxnard, G. R., Kris, M. G., Miller, V. A., Pao, W., Holodny, A. I., Clarke, J. L., & Lassman, A. B. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor121 · Cited by 349

Carcinomatous meningitis: Leptomeningeal metastases in solid tumors

Chamberlain, M. C., Rhun, É. L., & Taillibert, S. (2013) · Surgical Neurology International · doi:10.4103/2152-7806.111304 · Cited by 342

MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity

Teplyuk, N. M., Mollenhauer, B., Gabriely, G., Giese, A., Kim, E. L., Smolsky, M., Kim, R. Y., Saria, M. G., Pastorino, S., Kesari, S. P., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos074 · Cited by 304

Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer

Togashi, Y., Masago, K., Masuda, S., Mizuno, T., Fukudo, M., Ikemi, Y., Sakamori, Y., Nagai, H., Kim, Y. H., Katsura, T., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1929-4 · Cited by 282

Leptomeningeal metastasis from systemic cancer: Review and update on management

Wang, N., Bertalan, M. S., & Brastianos, P. K. (2017) · Cancer · doi:10.1002/cncr.30911 · Cited by 262

Efficacy of the Irreversible ErbB Family Blocker Afatinib in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)–Pretreated Non–Small-Cell Lung Cancer Patients with Brain Metastases or Leptomeningeal Disease

Hoffknecht, P., Tufman, A., Wehler, T., Pelzer, T., Wiewrodt, R. G., Schütz, M., Serke, M. H., Stöhlmacher-Williams, J., Märten, A., Huber, R. M., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000380 · Cited by 259

Systemic therapy of brain metastases: non–small cell lung cancer, breast cancer, and melanoma

Chamberlain, M. C., Baik, C. S., Gadi, V. K., Bhatia, S., & Chow, L. Q. M. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now197 · Cited by 224

Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors

Gion, P. D., Kanefendt, F., Lindauer, A., Scheffler, M., Doroshyenko, O., Fuhr, U., Wolf, J., & Jaehde, U. (2011) · Clinical Pharmacokinetics · doi:10.2165/11593320-000000000-00000 · Cited by 224

Development of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or Erlotinib

Héon, S., Yeap, B. Y., Britt, G. J., Costa, D. B., Rabin, M. S., Jackman, D. M., & Johnson, B. E. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1588 · Cited by 217

High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer

Clarke, J. L., Pao, W., Wu, N., Miller, V. A., & Lassman, A. B. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0128-6 · Cited by 214

The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung Cancer: Status in 2016

Tan, D. S. W., Yom, S. S., Tsao, M. S., Pass, H. I., Kelly, K., Peled, N., Yung, R. C., Wistuba, I. I., Yatabe, Y., Unger, M., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.05.008 · Cited by 201

Leptomeningeal carcinomatosis in non-small cell lung cancer patients: A continuing challenge in the personalized treatment era

Remón, J., Rhun, É. L., & Besse, B. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.12.006 · Cited by 196

Rebiopsy of non–small cell lung cancer patients with acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor: Comparison between T790M mutation‐positive and mutation‐negative populations

Hata, A., Katakami, N., Yoshioka, H., Takeshita, J., Tanaka, K., Nanjo, S., Fujita, S., Kaji, R., Imai, Y., Monden, K., et al. (2013) · Cancer · doi:10.1002/cncr.28364 · Cited by 178

The Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non–Small Cell Lung Cancer with EGFR Mutations

Heon, S., Yeap, B. Y., Lindeman, N. I., Joshi, V. A., Butaney, M., Britt, G. J., Costa, D. B., Rabin, M. S., Jackman, D. M., & Johnson, B. E. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0357 · Cited by 176

Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era

Park, J. H., Kim, Y. J., Lee, J., Lee, K., Kim, J. H., Bang, S., Chung, J.-H., Js, K., & Lee, J. S. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.11.022 · Cited by 170

Therapy of leptomeningeal metastasis in solid tumors

Mack, F., Baumert, B. G., Schäfer, N., Hattingen, E., Scheffler, B., Herrlinger, U., & Glas, M. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.12.004 · Cited by 172

Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients

Koivunen, J. P., Kim, J., Lee, J., Rogers, A. M., Park, J. O., Zhao, X., Naoki, K., Okamoto, I., Nakagawa, K., Yeap, B. Y., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604469 · Cited by 168

Efficacy of Erlotinib for Brain and Leptomeningeal Metastases in Patients with Lung Adenocarcinoma Who Showed Initial Good Response to Gefitinib

Katayama, T., Shimizu, J., Suda, K., Onozato, R., Fukui, T., Ito, S., Hatooka, S., Sueda, T., Hida, T., Yatabe, Y., et al. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181b62572 · Cited by 161

HER Family Receptor Abnormalities in Lung Cancer Brain Metastases and Corresponding Primary Tumors

Sun, M., Behrens, C., Feng, L., Ozburn, N. C., Tang, X., Yin, G., Komaki, R. U., Varella‐Garcia, M., Hong, W. K., Aldape, K., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2921 · Cited by 152

Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non–Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI

Hata, A., Katakami, N., Yoshioka, H., Kaji, R., Masago, K., Fujita, S., Imai, Y., Nishiyama, A., Ishida, T., Nishimura, Y., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000647 · Cited by 150

Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

Zeng, Q., Wang, J., Cheng, Z., Chen, K., Johnström, P., Varnäs, K., Li, D. Y., Yang, Z. F., & Zhang, X. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01073 · Cited by 151

Melanoma central nervous system metastases: current approaches, challenges, and opportunities

Cohen, J. V., Tawbi, H., Margolin, K. A., Amravadi, R., Bosenberg, M., Brastianos, P. K., Chiang, V., de Groot, J., Glitza, I. C., Herlyn, M., et al. (2016) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12538 · Cited by 150

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Treatment of Epidermal Growth Factor Receptor–Mutant Non–Small Cell Lung Cancer Metastatic to the Brain

Jamal‐Hanjani, M., & Spicer, J. F. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2529 · Cited by 146

Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer

Heffron, T. P. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00618 · Cited by 144

Activity of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients with Non-small Cell Lung Cancer Harboring Rare Epidermal Growth Factor Receptor Mutations

De Pas, T., Toffalorio, F., Manzotti, M., Fumagalli, C., Spitaleri, G., Catania, C., Delmonte, A., Giovannini, M., Spaggiari, L., de Braud, F., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318227e8c6 · Cited by 138

ALK inhibitors in non-small cell lung cancer: the latest evidence and developments

Sullivan, I., & Planchard, D. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015617355 · Cited by 139

Cerebrospinal Fluid Concentration of Erlotinib and its Active Metabolite OSI-420 in Patients with Central Nervous System Metastases of Non-small Cell Lung Cancer

Togashi, Y., Masago, K., Fukudo, M., Terada, T., Fujita, S., Irisa, K., Sakamori, Y., Kim, Y. H., Mio, T., Inui, K., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181e2138b · Cited by 130

Leptomeningeal Metastasis from Non–Small Cell Lung Cancer and Current Landscape of Treatments

Ozcan, G., Singh, M., & Vredenburgh, J. J. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1585 · Cited by 126

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI

Yi, H. G., Kim, H. J., Kim, Y. J., Han, S., Oh, D., Lee, S., Kim, D., Im, S., Kim, T., Kim, C. S., et al. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2008.10.016 · Cited by 125

When Progressive Disease Does Not Mean Treatment Failure: Reconsidering the Criteria for Progression

Oxnard, G. R., Morris, M. J., Hodi, F. S., Baker, L. H., Kris, M. G., Venook, A. P., & Schwartz, L. H. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs353 · Cited by 126

Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group

Umemura, S., Tsubouchi, K., Yoshioka, H., Hotta, K., Takigawa, N., Fujiwara, K., Horita, N., Segawa, Y., Hamada, N., Takata, I., et al. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.03.002 · Cited by 122

Cerebrospinal Fluid Concentrations of Gefitinib in Patients With Lung Adenocarcinoma

Zhao, J., Chen, M., Zhong, W., Zhang, L., Li, L., Xiao, Y., Nie, L., Hu, P., & Wang, M. (2012) · Clinical Lung Cancer · doi:10.1016/j.cllc.2012.06.004 · Cited by 121

Erlotinib Versus Gefitinib for Control of Leptomeningeal Carcinomatosis in Non–Small-Cell Lung Cancer

Lee, E., Keam, B., Kim, D., Kim, T. M., Lee, S., Chung, D. H., & Heo, D. S. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318294c8e8 · Cited by 121

Blood-brain barrier permeability of gefitinib in patients with brain metastases from non-small-cell lung cancer before and during whole brain radiation therapy

Zeng, Y.-D., Liao, H., Qin, T., Zhang, L., Wei, W.-D., Liang, J.-Z., Xu, F., Dinglin, X.-X., Ma, S.-X., & Chen, L.-K. (2015) · Oncotarget · doi:10.18632/oncotarget.3187 · Cited by 112

Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors

Scheffler, M., Gion, P. D., Doroshyenko, O., Wolf, J., & Fuhr, U. (2011) · Clinical Pharmacokinetics · doi:10.2165/11587020-000000000-00000 · Cited by 110

Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall‐cell lung cancer

Lee, Y. J., Choi, H. J., Kim, S. I., Chang, J., Moon, J. W., Park, I. K., Kim, J.-H., & Cho, B. C. (2010) · Cancer · doi:10.1002/cncr.24877 · Cited by 106

A Phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer

Jackman, D. M., Cioffredi, L. A., Jacobs, L., Sharmeen, F., Morse, L. K., Lucca, J. V., Plotkin, S. R., Marcoux, P. J., Rabin, M. S., Lynch, T. J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.2886 · Cited by 101

Leptomeningeal Disease

Groves, M. D. (2010) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2010.08.006 · Cited by 100

Epidermal Growth Factor Receptor Abnormalities in the Pathogenesis and Progression of Lung Adenocarcinomas

Tang, X., Varella‐Garcia, M., Xavier, A. C., Massarelli, E., Ozburn, N. C., Moran, C. A., & Wistuba, I. I. (2008) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-08-0032 · Cited by 99

Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy

Masuda, T., Hattori, N., Hamada, A., Iwamoto, H., Ohshimo, S., Kanehara, M., Ishikawa, N., Fujitaka, K., Haruta, Y., Murai, H., et al. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1555-6 · Cited by 97

Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status

Lee, J., Choi, Y., Han, J., Park, S., Jung, H. A., Su, J.-M., Lee, S., Ahn, J. S., Park, K., & Ahn, M. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.06.018 · Cited by 90

Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure

Shukuya, T., Takahashi, T., Naito, T., Kaira, R., Ono, A., Nakamura, Y., Tsuya, A., Kenmotsu, H., Murakami, H., Harada, H., et al. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.04.007 · Cited by 90

Management of Brain Metastases in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer

Kelly, W., Shah, N. J., & Subramaniam, D. S. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00208 · Cited by 86

Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma

Cadranel, J. L., Ruppert, A.-M., Beau‐Faller, M., & Wislez, M. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.06.009 · Cited by 83

Leptomeningeal metastasis

Taillibert, S., & Chamberlain, M. C. (2018) · Handbook of clinical neurology · doi:10.1016/b978-0-12-811161-1.00013-x · Cited by 81

Clinical Impact of Continued Crizotinib Administration after Isolated Central Nervous System Progression in Patients with Lung Cancer Positive for ALK Rearrangement

Takeda, M., Okamoto, I., & Nakagawa, K. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31828c28e7 · Cited by 80

Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment

Remón, J., & Besse, B. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00088 · Cited by 80

Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation

Togashi, Y., Masago, K., Fukudo, M., Tsuchido, Y., Okuda, C., Kim, Y. H., Ikemi, Y., Sakamori, Y., Mio, T., Katsura, T., et al. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1691-z · Cited by 79

Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives

Chen, H., & Cheng, X. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s66502 · Cited by 81

High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIs

Kawamura, T., Hata, A., Takeshita, J., Fujita, S., Hayashi, M., Tomii, K., & Katakami, N. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2759-y · Cited by 77

Targeted Therapy for Brain Metastases in EGFR-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer

Baik, C. S., Chamberlain, M. C., & Chow, L. Q. M. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000615 · Cited by 77

Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations

Tam, I. Y. S., Leung, E. L., Tin, V. P., Chua, D. T.-T., Sihoe, A. D., Cheng, L., Chung, L.-P., & Wong, M. P. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-1219 · Cited by 76

CNS metastases in non-small-cell lung cancer: Current role of EGFR-TKI therapy and future perspectives

Berger, L. A., Riesenberg, H., Bokemeyer, C., & Atanackovic, D. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.02.004 · Cited by 73

Gefitinib Alone or with Concomitant Whole Brain Radiotherapy for Patients with Brain Metastasis from Non-small-cell Lung Cancer: A Retrospective Study

Zeng, Y.-D., Zhang, L., Liao, H., Liang, Y., Xu, F., Liu, J., Dinglin, X.-X., & Chen, L.-K. (2012) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2012.13.3.909 · Cited by 72

Evaluation of Polymer Nanoformulations in Hepatoma Therapy by Established Rodent Models

Wang, Q., Zhang, P., Li, Z., Feng, X., Lv, C., Zhang, H., Xiao, H., Ding, J., & Chen, X. (2019) · Theranostics · doi:10.7150/thno.31683 · Cited by 72

EGFR mutation status in brain metastases of non-small cell lung carcinoma

Burel‐Vandenbos, F., Ambrosetti, D., Coutts, M., & Pédeutour, F. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-0990-5 · Cited by 72

EGFR mutations are associated with favorable intracranial response and progression-free survival following brain irradiation in non-small cell lung cancer patients with brain metastases

Lee, H., Chung, T.-S., Ting, L., Tsai, J., Chen, S.-W., Chiou, J., Leung, H. W.-C., & Liu, H. E. (2012) · Radiation Oncology · doi:10.1186/1748-717x-7-181 · Cited by 65

Management of epidermal growth factor receptor tyrosine kinase inhibitor‐related cutaneous and gastrointestinal toxicities

Aw, D. C., Tan, E. H., Chin, T. M., Lim, H. L., Lee, H. Y., & Soo, R. A. (2017) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12687 · Cited by 69

Emerging treatment paradigms for brain metastasis in non-small-cell lung cancer: an overview of the current landscape and challenges ahead

Ulahannan, D., Khalifa, J., Finn, C. F., & Lee, S. M. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx481 · Cited by 63

Carcinomatous Meningitis in Non–Small-Cell Lung Cancer: Response to High-Dose Erlotinib

Dhruva, N., & Socinski, M. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.0963 · Cited by 64

Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of central nerve system metastases from non-small cell lung cancer

Zhang, J., Yu, J., Sun, X., & Meng, X. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.04.019 · Cited by 63

Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature

Jacus, M. O., Daryani, V. M., Harstead, K. E., Patel, Y. T., Throm, S. L., & Stewart, C. F. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0319-6 · Cited by 60

Local Therapy for Oligoprogressive Disease in Patients With Advanced Stage Non–small-cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation

Qiu, B., Liang, Y., Li, Q.-W., Liu, G.-H., Wang, F., Chen, Z., Liu, M., Zhao, M. D., & Liu, H. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.04.002 · Cited by 61

Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer

Baek, M. Y., Ahn, H. K., Park, K. R., Park, H.-S., Kang, S. M., Park, I., Kim, Y. S., Hong, J., Sym, S. J., Park, J., et al. (2016) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2015.158 · Cited by 54

Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure

Sasaki, S., Yoshioka, Y., Ko, R., Katsura, Y., Namba, Y., Shukuya, T., Kido, K., Iwakami, S., Tominaga, S., & Takahashi, K. (2015) · Respiratory Investigation · doi:10.1016/j.resinv.2015.07.001 · Cited by 53

EGFR mutation status of paired cerebrospinal fluid and plasma samples in EGFR mutant non-small cell lung cancer with leptomeningeal metastases

Zhao, J., Ye, X., Xu, Y., Chen, M., Zhong, W., Sun, Y., Yang, Z., Zhu, G., Gu, Y., & Wang, M. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3155-y · Cited by 53

Pulsatile Erlotinib in EGFR-Positive Non–Small-Cell Lung Cancer Patients With Leptomeningeal and Brain Metastases: Review of the Literature

How, J., Mann, J., Laczniak, A. N., & Baggstrom, M. Q. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.01.013 · Cited by 52

High-dose Erlotinib for Refractory Brain Metastases in a Patient with Relapsed Non-small Cell Lung Cancer

Hata, A., Kaji, R., Fujita, S., & Katakami, N. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181d899bb · Cited by 50

Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement–Positive Non–Small-Cell Lung Cancer

Kaneda, H., Okamoto, I., & Nakagawa, K. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182843771 · Cited by 50

Targeted Therapies in Brain Metastases

Lin, N. (2013) · Current Treatment Options in Neurology · doi:10.1007/s11940-013-0276-z · Cited by 49

Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis

Chen, Y., Wang, M., Zhong, W., & Zhao, J. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.08.013 · Cited by 48

Management of brain metastasized non-small cell lung cancer (NSCLC) – From local treatment to new systemic therapies

Tsakonas, G., Petris, L. D., & Ekman, S. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.02.004 · Cited by 48

Management of brain metastases in non-small cell lung cancer in the era of tyrosine kinase inhibitors

Wrona, A., Dziadziuszko, R., & Jassem, J. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.10.011 · Cited by 48

High-dose, pulsatile erlotinib in two NSCLC patients with leptomeningeal metastases—one with a remarkable thoracic response as well

Kuiper, J. L., & Smit, E. F. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2012.12.024 · Cited by 46

Treatment options for EGFR mutant NSCLC with CNS involvement—Can patients BLOOM with the use of next generation EGFR TKIs?

Tan, C., Cho, B. C., & Soo, R. A. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.02.012 · Cited by 45

EGFR tyrosine kinase inhibitors beyond focal progression obtain a prolonged disease control in patients with advanced adenocarcinoma of the lung

Conforti, F., Catania, C., Toffalorio, F., Duca, M., Spitaleri, G., Barberis, M. C. P., Noberasco, C., Delmonte, A., Santarpía, M., Lazzari, C., et al. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.05.019 · Cited by 43

EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up

Ruppert, A.-M., Beau‐Faller, M., Neuville, A., Guérin, É., Voegeli, A.-C., Mennecier, B., Legrain, M., Molard, A., Jeung, M.-Y., Gaub, M.-P., et al. (2009) · European Respiratory Journal · doi:10.1183/09031936.00162307 · Cited by 44

Impact of whole brain radiation therapy on CSF penetration ability of Icotinib in EGFR-mutated non-small cell lung cancer patients with brain metastases: Results of phase I dose-escalation study

Zhou, L., He, J., Xiong, W., Liu, Y., Xiang, J., Yu, Q., Liang, M., Zhou, X., Ding, Z., Huang, M., et al. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.04.003 · Cited by 40

High-Dose Crizotinib for Brain Metastases Refractory to Standard-Dose Crizotinib

Kim, Y. H., Ozasa, H., Nagai, H., Sakamori, Y., Yoshida, H., Yagi, Y., Nakaoku, T., & Mishima, M. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31829cebbb · Cited by 39

Novel approaches to treating leptomeningeal metastases

Grewal, J., Saria, M. G., & Kesari, S. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0686-2 · Cited by 39

Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancer

Yap, T. A., Macklin-Doherty, A., & Popat, S. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.10.014 · Cited by 38

Erlotinib for the treatment of brain metastases in non-small cell lung cancer

Brower, J. V., & Robins, H. I. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1165206 · Cited by 37

Spectrum of human papillomavirus-related dysplasia and carcinoma of the anus in HIV-infected patients.

Panther, L., Schlecht, H. P., & Dezube, B. J. (2005) · PubMed · Cited by 24

Anale intraepitheliale Neoplasie und Analkarzinom

Kreuter, A., Brockmeyer, N. H., & Wieland, U. (2009) · Der Hautarzt · doi:10.1007/s00105-009-1810-5 · Cited by 14

Anal cancer and its precursors in HIV-positive patients: perspectives and management

Berry, J. M., Palefsky, J. M., & Welton, M. L. (2004) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2003.12.003 · Cited by 93

HPV-Associated Anal Cancer in the HIV/AIDS Patient

Wang, C.-C. J., & Palefsky, J. M. (2018) · Cancer treatment and research · doi:10.1007/978-3-030-03502-0_7 · Cited by 63

Anal intraepithelial neoplasia and squamous cell carcinoma in HIV ‐infected adults

Tong, W., Hillman, R. J., Kelleher, A. D., Grulich, A., & Carr, A. D. (2013) · HIV Medicine · doi:10.1111/hiv.12080 · Cited by 42